|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
ES2669310T3
(es)
*
|
2011-04-20 |
2018-05-24 |
Medimmune, Llc |
Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
|
|
WO2012154983A2
(en)
|
2011-05-10 |
2012-11-15 |
Biocare Medical, Llc |
Systems and methods for anti-pax8 antibodies
|
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
|
EP3939613A1
(en)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
|
US10316103B1
(en)
|
2012-03-30 |
2019-06-11 |
Biocare Medical, Llc |
Systems and methods for anti-Uroplakin III antibodies
|
|
EP2900265B1
(en)
|
2012-09-27 |
2018-05-30 |
Biocare Medical, LLC |
Anti-uroplakin ii antibodies systems and methods
|
|
US10429390B2
(en)
|
2012-12-18 |
2019-10-01 |
Biocare Medical, Llc |
Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
|
|
ES2720483T3
(es)
|
2013-02-28 |
2019-07-22 |
Biocare Medical Llc |
Sistemas y procedimientos de anticuerpos anti p40
|
|
SG11201508528TA
(en)
|
2013-05-02 |
2015-11-27 |
Anaptysbio Inc |
Antibodies directed against programmed death-1 (pd-1)
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
EP3659622A1
(en)
|
2013-08-08 |
2020-06-03 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
PL3444271T3
(pl)
|
2013-08-08 |
2022-03-07 |
Cytune Pharma |
Modulokiny oparte na il-15 i domenie sushi il-15ralfa
|
|
PT3702373T
(pt)
|
2013-09-13 |
2022-09-27 |
Beigene Switzerland Gmbh |
Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US9816997B2
(en)
|
2013-10-03 |
2017-11-14 |
Biocare Medical, Llc |
Anti-SOX10 antibody systems and methods
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
CN114081946A
(zh)
|
2014-03-12 |
2022-02-25 |
耶达研究与开发有限公司 |
降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
CA2936962C
(en)
|
2014-03-14 |
2024-03-05 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
JP6526189B2
(ja)
|
2014-07-03 |
2019-06-05 |
ベイジーン リミテッド |
抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
|
|
EP3171892B1
(en)
|
2014-07-22 |
2021-11-24 |
Apollomics Inc. |
Anti-pd-1 antibodies
|
|
PL3177644T3
(pl)
|
2014-08-05 |
2021-06-14 |
MabQuest SA |
Immunologiczne reagenty wiążące do PD-1
|
|
RU2722212C9
(ru)
|
2014-08-05 |
2020-07-23 |
СиБи ТЕРЕПЬЮТИКС, ИНК. |
Анти-pd-l1 антитела
|
|
US9982052B2
(en)
*
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
CA2960824A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
EP3215182B1
(en)
|
2014-11-05 |
2023-01-04 |
The Regents of The University of California |
Combination immunotherapy
|
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
|
RU2752729C2
(ru)
|
2015-05-18 |
2021-07-30 |
Сумитомо Даиниппон Фарма Онколоджи, Инк. |
Пролекарства альвоцидиба, имеющие повышенную биодоступность
|
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
US10513558B2
(en)
|
2015-07-13 |
2019-12-24 |
Cytomx Therapeutics, Inc. |
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
|
|
MA42459A
(fr)
|
2015-07-16 |
2018-05-23 |
Bioxcel Therapeutics Inc |
Nouvelle approche pour le traitement du cancer par immunomodulation
|
|
EP3331918A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
KR20180036996A
(ko)
|
2015-08-04 |
2018-04-10 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 치료 및 그의 용도 및 방법
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
KR20220131277A
(ko)
|
2015-09-01 |
2022-09-27 |
아게누스 인코포레이티드 |
항-pd-1 항체 및 이를 이용하는 방법
|
|
EP3355920A4
(en)
|
2015-09-29 |
2019-05-15 |
Celgene Corporation |
PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
MA43018B1
(fr)
|
2015-10-02 |
2021-11-30 |
Hoffmann La Roche |
Anticorps anti-pd1 et procédés d'utilisation
|
|
MY190324A
(en)
*
|
2015-10-02 |
2022-04-14 |
Symphogen As |
Anti-pd-1 antibodies and compositions
|
|
RS62258B1
(sr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Bispecifična antitela specifična za pd1 i tim3
|
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
|
BR112018012801B1
(pt)
|
2015-12-22 |
2024-03-12 |
Regeneron Pharmaceuticals, Inc |
Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
WO2017125815A2
(en)
|
2016-01-22 |
2017-07-27 |
MabQuest SA |
Immunological reagents
|
|
US11180546B2
(en)
|
2016-02-17 |
2021-11-23 |
Novartis Ag |
TGFbeta 2 antibodies
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
US11760803B2
(en)
|
2016-03-24 |
2023-09-19 |
Takeda Pharmaceutical Company Limited |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
JP7185530B2
(ja)
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス， インコーポレイテッド |
免疫細胞機能を促進するための方法および組成物
|
|
WO2017220989A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
CN118252927A
(zh)
|
2016-08-19 |
2024-06-28 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
EP3858365B1
(en)
|
2016-09-01 |
2024-01-31 |
Chimera Bioengineering Inc. |
Gold optimized car t-cells
|
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
|
AU2017329024A1
(en)
|
2016-09-19 |
2019-03-21 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
BR112019007369A2
(pt)
|
2016-10-11 |
2019-07-16 |
Agenus Inc |
anticorpos anti-lag-3 e métodos de uso dos mesmos
|
|
MA49863A
(fr)
|
2016-11-01 |
2020-06-17 |
Anaptysbio Inc |
Anticorps dirigés contre la mort programmée 1 (pd -1)
|
|
UY37463A
(es)
|
2016-11-02 |
2018-05-31 |
Glaxosmithkline Ip No 2 Ltd |
Proteínas de unión
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018091661A1
(en)
|
2016-11-18 |
2018-05-24 |
Symphogen A/S |
Anti-pd-1 antibodies and compositions
|
|
WO2018100535A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
JP2020500878A
(ja)
|
2016-12-01 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
MA50949B1
(fr)
|
2016-12-07 |
2023-12-29 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
PL3565844T3
(pl)
|
2017-01-09 |
2023-06-12 |
Tesaro Inc. |
Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1
|
|
AU2018207172B2
(en)
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
EP3571231A4
(en)
|
2017-01-20 |
2020-12-02 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
ANTI-PD-1 ANTIBODIES AND THEIR USES
|
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
CN108341871A
(zh)
*
|
2017-01-24 |
2018-07-31 |
三生国健药业（上海）股份有限公司 |
抗pd-1单克隆抗体及其制备方法和应用
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
KR20190115053A
(ko)
|
2017-02-10 |
2019-10-10 |
노파르티스 아게 |
1-(4-아미노-5-브로모-6-(1h-피라졸-1-일)피리미딘-2-일)-1h-피라졸-4-올 및 암 치료에 있어서의 이의 용도
|
|
WO2018150326A1
(en)
|
2017-02-15 |
2018-08-23 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
CA3056630A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
JP7426825B2
(ja)
|
2017-04-03 |
2024-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
|
|
US11285207B2
(en)
|
2017-04-05 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specifically binding to PD1 and LAG3
|
|
AU2018247916B2
(en)
|
2017-04-05 |
2025-04-24 |
Les Laboratoires Servier |
Combination therapies targeting PD-1, TIM-3, and LAG-3
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
EP3618863B1
(en)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
|
WO2018226580A2
(en)
|
2017-06-05 |
2018-12-13 |
Janssen Biotech, Inc. |
Antibodies that specifically bind pd-1 and methods of use
|
|
WO2018225033A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TW201904993A
(zh)
|
2017-06-22 |
2019-02-01 |
瑞士商諾華公司 |
IL-1β 結合抗體之用途
|
|
JP2020525411A
(ja)
|
2017-06-26 |
2020-08-27 |
ベイジーン リミテッド |
肝細胞癌のための免疫療法
|
|
MX2019015738A
(es)
|
2017-06-27 |
2020-02-20 |
Novartis Ag |
Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
|
|
BR112020000228A2
(pt)
|
2017-07-06 |
2020-07-14 |
Merus N.V. |
anticorpos que modulam uma atividade biológica expressa por célula
|
|
AU2018302283B2
(en)
|
2017-07-20 |
2025-07-10 |
Novartis Ag |
Dosage regimens of anti-LAG-3 antibodies and uses thereof
|
|
CA3073055A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
AU2018375738A1
(en)
|
2017-11-30 |
2020-06-11 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
TWI804572B
(zh)
|
2018-02-09 |
2023-06-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
AR114127A1
(es)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
Anticuerpos agonistas contra pd-1 y usos de estos
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
EP3784688A2
(en)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
US20210363216A1
(en)
|
2018-05-14 |
2021-11-25 |
Immunocore Limited |
Bifunctional binding polypeptides
|
|
AU2019269628A1
(en)
*
|
2018-05-17 |
2020-12-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor inhibition by phosphatase recruitment
|
|
TWI806870B
(zh)
*
|
2018-05-23 |
2023-07-01 |
中國大陸商大有華夏生物醫藥集團有限公司 |
抗pd-1抗體及其用途
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN118459594A
(zh)
|
2018-06-01 |
2024-08-09 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
CN120714025A
(zh)
|
2018-06-20 |
2025-09-30 |
因赛特公司 |
抗pd-1抗体及其用途
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
WO2020015722A1
(en)
|
2018-07-19 |
2020-01-23 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-1 antibodies, dosages and uses thereof
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
US20200046768A1
(en)
*
|
2018-08-09 |
2020-02-13 |
University Health Network |
Double negative t cells and pd-1 blockade for the treatment of cancer
|
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
WO2020061142A1
(en)
*
|
2018-09-18 |
2020-03-26 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
CN112867803A
(zh)
|
2018-10-16 |
2021-05-28 |
诺华股份有限公司 |
单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
|
|
WO2020086476A1
(en)
|
2018-10-22 |
2020-04-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
CA3119311A1
(en)
|
2018-11-09 |
2020-05-14 |
Pierian Biosciences, LLC |
Methods and compositions for determining the composition of a tumor microenvironment
|
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
US20200369762A1
(en)
|
2018-12-21 |
2020-11-26 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
MX2021007271A
(es)
|
2018-12-21 |
2021-07-15 |
Onxeo |
Nuevas moleculas de acido nucleico conjugado y sus usos.
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
KR20210108422A
(ko)
|
2018-12-21 |
2021-09-02 |
노파르티스 아게 |
IL-1β 결합 항체의 용도
|
|
CN111423510B
(zh)
|
2019-01-10 |
2024-02-06 |
迈威(上海)生物科技股份有限公司 |
重组抗人pd-1抗体及其应用
|
|
KR20210126652A
(ko)
|
2019-02-12 |
2021-10-20 |
노파르티스 아게 |
Tno155 및 pd-1 억제제를 포함하는 약제학적 조합물
|
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
US12479817B2
(en)
|
2019-02-15 |
2025-11-25 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020222345B2
(en)
|
2019-02-15 |
2022-11-17 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
JP7547360B2
(ja)
|
2019-03-22 |
2024-09-09 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
CA3141327A1
(en)
|
2019-05-20 |
2020-11-26 |
Pandion Operations, Inc. |
Madcam targeted immunotolerance
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
US20220233685A1
(en)
|
2019-06-18 |
2022-07-28 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
US20220372148A1
(en)
|
2019-07-05 |
2022-11-24 |
Ono Pharmaceutical Co., Ltd. |
A pharmaceutical composition for treating hematological cancer
|
|
US20220252599A1
(en)
*
|
2019-07-12 |
2022-08-11 |
The Johns Hopkins University |
Compositions and methods for treating cerebral vasospasm
|
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
|
US20220411388A1
(en)
|
2019-09-17 |
2022-12-29 |
Bial - R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
|
AU2020349519A1
(en)
|
2019-09-17 |
2022-03-17 |
Bial-R&D Investments, S.A. |
Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
|
EP4031540A1
(en)
|
2019-09-17 |
2022-07-27 |
Bial-R&D Investments, S.A. |
Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
KR20220103947A
(ko)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
베네토클락스 및 tim-3 억제제를 사용한 조합 요법
|
|
CN114786680A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Tim-3抑制剂及其用途
|
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
JP2023506958A
(ja)
|
2019-12-20 |
2023-02-20 |
ノバルティス アーゲー |
骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
|
|
IL293752A
(en)
|
2020-01-17 |
2022-08-01 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
WO2021171260A2
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor or a pd-1 inhibitor
|
|
WO2022074464A2
(en)
|
2020-03-05 |
2022-04-14 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
CN115698075A
(zh)
|
2020-04-14 |
2023-02-03 |
葛兰素史密斯克莱知识产权发展有限公司 |
涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗
|
|
WO2021209356A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
KR20230004635A
(ko)
|
2020-04-21 |
2023-01-06 |
노파르티스 아게 |
Csf-1r에 의해 조절되는 질병을 치료하기 위한 투여 요법
|
|
LT4157876T
(lt)
|
2020-05-26 |
2024-10-25 |
Boehringer Ingelheim International Gmbh |
Anti-pd-1 antikūnai
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
PE20231082A1
(es)
|
2020-06-26 |
2023-07-17 |
Amgen Inc |
Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas
|
|
JP2023532339A
(ja)
|
2020-06-29 |
2023-07-27 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
|
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
WO2022169825A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
EP4314062A1
(en)
|
2021-03-31 |
2024-02-07 |
Merus N.V. |
Novel pd-1 binding domains
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
BR112023021111A2
(pt)
|
2021-04-13 |
2023-12-19 |
Nuvalent Inc |
Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2
|
|
IL307887A
(en)
*
|
2021-05-13 |
2023-12-01 |
Foundation For Biomedical Res And Innovation At Kobe |
Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
WO2023028501A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
US20240425571A1
(en)
*
|
2021-10-11 |
2024-12-26 |
Ohio State Innovation Foundation |
Glycoprotein a repetitions predominant (garp)-binding antibodies and uses thereof
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
EP4429717A1
(en)
|
2021-11-12 |
2024-09-18 |
Novartis AG |
Combination therapy for treating lung cancer
|
|
CN118660964A
(zh)
|
2021-12-16 |
2024-09-17 |
瓦莱里奥治疗公司 |
新型缀合核酸分子及其用途
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2023285094A1
(en)
|
2022-06-08 |
2025-01-23 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
EP4658310A1
(en)
|
2023-01-30 |
2025-12-10 |
Kymab Limited |
Antibodies
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024228167A1
(en)
|
2023-05-03 |
2024-11-07 |
Iox Therapeutics Inc. |
Inkt cell modulator liposomal compositions and methods of use
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025207705A1
(en)
|
2024-03-26 |
2025-10-02 |
Amgen Inc. |
Cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025213154A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
|